News MS Patients Are Adequately, But Not Optimally, Treated for Depression MS Patients Are Adequately, But Not Optimally, Treated for Depression by Patricia Silva, PhD | December 29, 2015 Share this article: Share article via email Copy article link A new Canadian study, published in the International Journal of MS Care, has concluded that the majority of patients with concurrent multiple sclerosis (MS) and depression are receiving antidepressant treatment. Despite this, however, many of these patients continue to report depressive symptoms. MS and depression co-occurrence is a big concern, and some reports estimate that up toĀ 50%Ā of MS patients suffer from depression at some time point in their life. Earlier studies have also shown that a large proportion of MS patients ā up to 65% ā do not receive adequate treatment for their depressive symptoms. The new study byĀ Aida Raissi and colleagues atĀ Hotchkiss Brain Institute set out to investigate how many MS patients received drug treatment for depression. The study, titledĀ “Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis,“Ā also aimedĀ to determine whichĀ types of treatment were usedĀ and to identify characteristics of patients receiving antidepressant drugs. Using a large number of questionnaires and assessment tools for depression, antidepressant treatment, and MS ā as well as measurements for investigating neurological impairmentĀ andĀ quality of life ā researchers screened 152 people at an outpatient MS clinic in Calgary, Canada. The study found that 13% of the participants were currently depressed, and 39% reported being depressed at some point in their lives. Of those currently depressed, 65% were taking antidepressant agents. No specific characteristics wereĀ associated with antidepressant use, but the team observed that women and older individuals wereĀ slightlyĀ overrepresented, a trend that might mirror antidepressantĀ demographics in the general population. Antidepressant drugs were not the sole treatment employed in thisĀ group of patients; 19% received only non-drug treatment (psychotherapy), and a further 44% combined drug use and psychotherapy. The team then adjusted the analysis by taking into consideration patients using antidepressants without having depressive symptoms, and found that 86% of the depressed MS patients received treatment for their depression ā a significant improvement from previous reports. While the authors note a significant improvement in antidepressant treatment coverage in this MS cohort compared to previous reports, they raise some concerns regarding the generalization of their results. Canada is the world’s third leading consumer of antidepressant drugs, behind Iceland and Australia. Considering the study’s small size (152 patients), the findingsĀ might not be relevant inĀ other countries. The team also found that a relatively large proportion of patients wereĀ having depressive symptoms in spite of their treatment. The study, however, did not report treatment dose or duration,Ā and the authors argue that further research is needed to explore the reasons for a lack of treatment response. Previously developed guidelines for the treatment of depression in MS by theĀ Canadian Network for Mood and Anxiety TreatmentsĀ recommends usingĀ antidepressant drugs in combination with psychotherapy focusing on coping strategies. The authors, therefore, noted that the lack of treatment responseĀ might mirror the high proportion of patients (38%) receiving only drug therapy. The study concludes that, since treatment seems to be reaching most depressed patients, optimization of treatment strategies should be a priority for physicians treatingĀ MS patients with concurrent depression. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Canada, depression
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year